Candel Therapeutics (CADL) Operating Leases (2022 - 2025)

Candel Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• In Q4 2025, Operating Leases rose 258.48% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 258.48% YoY), while the FY2025 annual figure was $1.5 million, up 258.48% from the prior year.
• Operating Leases came in at $1.5 million for Q4 2025 at Candel Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.8 million in Q1 2022 to a low of $104000.0 in Q2 2025.
• A 4-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Operating Leases.
• On a YoY basis, Operating Leases climbed as much as 258.48% in 2025 and fell as far as 85.1% in 2025.
• Candel Therapeutics' Operating Leases stood at $1.5 million in 2022, then plunged by 34.52% to $973000.0 in 2023, then tumbled by 58.17% to $407000.0 in 2024, then soared by 258.48% to $1.5 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $1.5 million, $1.6 million, and $104000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison